Related Experiment Video
Updated: May 7, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
Alexander Swarbrick1, Simon R Junankar, Marcel Batten
1Cancer Division; Garvan Institute of Medical Research; Sydney, NSW Australia ; St. Vincent's Clinical School; University of New South Wales; Sydney, NSW Australia.
Abstract:
We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

